United States Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2024-2032

United States Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A5509
Buy Now

Market Overview:

The United States idiopathic pulmonary fibrosis treatment market size reached US$ 2,684.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 4,741.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.53% during 2024-2032.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 2,684.4 Million
Market Forecast in 2032
US$ 4,741.4 Million
Market Growth Rate 2024-2032 6.53%


Idiopathic pulmonary fibrosis (IPF) is a form of progressive lung disease that causes a buildup of scar tissues in the lungs. This condition hinders the oxygen-carrying functionality of the lungs, thus resulting in breathing difficulties. IPF is diagnosed through various chest imaging evaluations, including antibody tests, lung biopsies, and pulmonary function tests. It can be treated by prescribing anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.

 

 
 

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

United States Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially among the geriatric population, represents the key factor driving the IPF treatment market growth in the United States. Changing living standards and the increasing consumption of nicotine-based products are further catalyzing the market growth. Other than this, increasing health consciousness, rising awareness regarding the availability of effective strategies for managing IPF, and rapid advancements in diagnostic techniques are propelling the market growth. Moreover, extensive research and development (R&D) activities for introducing novel medicines are creating a positive outlook for the market in the country.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the United States idiopathic pulmonary fibrosis treatment market report, along with forecasts at the country and regional level from 2024-2032. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

 

 
 

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors
     

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others
     

Breakup by Region:

  • Northeast
  • Midwest
  • South
  • West


Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Segment Coverage Drug Class, End User, Region
Region Covered Northeast, Midwest, South, West
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The United States idiopathic pulmonary fibrosis treatment market was valued at US$ 2,684.4 Million in 2023.

We expect the United States idiopathic pulmonary fibrosis treatment market to exhibit a CAGR of 6.53% during 2024-2032.

The rising prevalence of chronic lung and fibrotic diseases, along with the growing consumer awareness regarding the presence of effective idiopathic pulmonary fibrosis preventive and management treatment, is primarily driving the United States idiopathic pulmonary fibrosis treatment market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective idiopathic pulmonary fibrosis treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.

Based on the drug class, the United States idiopathic pulmonary fibrosis treatment market has been bifurcated into MAPK inhibitors, tyrosine inhibitors, and autotaxin inhibitors. Among these, tyrosine inhibitors currently hold the majority of the total market share.

Based on the end user, the United States idiopathic pulmonary fibrosis treatment market can be segmented into hospitals, long-term care facilities, and others. Currently, hospitals exhibit a clear dominance in the market.

On a regional level, the market has been classified into Northeast, Midwest, South, and West.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
United States Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More